Navigation Links
Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
Date:9/22/2008

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- Napo Pharmaceuticals (LSE: NAPL/NAPU) today announces positive clinical data on the effectiveness of crofelemer from a study for CRO-ID in treating severely ill cholera patients in conjunction with an antibiotic and rehydration therapy.

A double-blind placebo-controlled study was conducted in one hundred (100) patients with confirmed severe cholera. Patients were randomized to placebo or 125 mg crofelemer every 6 hours or 250 mg crofelemer every 6 hours in a 1:2:2 randomization scheme. This single center trial was conducted at the International Centre for Diarrhoeal Disease Research (ICDDR, B) in Dhaka, Bangladesh, popularly known as the "cholera hospital" for the state-of-the-art treatment of cholera patients.

The purpose of the trial was to obtain a therapeutic proof-of-concept in the treatment of cholera, by a reduction in the life-threatening fluid loss characteristic of cholera infection. In addition to receiving crofelemer, all patients received a single oral dose of azithromycin and rehydration therapy. These severely ill cholera patients, even when receiving the antibiotic azithromycin and rehydration therapy (but not crofelemer), averaged approximately 8.5 liters of stool volume output during the first 24 hour period. The primary endpoint in this study was the reduction in stool volume output normalized to the body weight of the cholera patients.

Following the exclusion of three outlier patients, the data demonstrates that a crofelemer dose of 125 mg every 6 hours reduced the amount of stool volume output normalized to body weight by 32% (p=0.028, Mann-Whitney test) in the first 6 hour period (0-6 hours). A 31% reduction in normalized stool volume output was also observed during the first 12 hour period (0-12 hours) with crofelemer 125 mg every 6 hours (p=0.072, Mann-Whitney test). The higher dose of crofelemer (250 mg every 6 hours) also showed a trend towards significance in the first 12
'/>"/>

SOURCE Napo Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
2. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
3. Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
4. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
5. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
6. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
7. Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial
8. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
9. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
10. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
11. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... the Company,s subsidiary Guizhou Taibang Biological Products Co., ... agreement (the "Agreement") with Xinjiang Deyuan Bioengineering Co., ... Agreement allows Guizhou Taibang to source no less ...
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 ... developing novel therapies for the treatment of chronic pain, ... investor meetings at both the FBR Second Annual Healthcare ... are as follows: FBR Second Annual Healthcare ... Seasons, Boston No presentation, ...
(Date:9/2/2015)... , Sept. 2, 2015  Kastle Therapeutics ... and commercializing pharmaceuticals for diseases with high unmet ... 3 executives to key commercial operating positions. ... Vice President, Commercial; Sean was previously Global Marketing ... been appointed as Director, Commercial Strategy and Analytics; ...
Breaking Medicine Technology:China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 2China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 3China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 4China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 5Relmada Therapeutics to Participate in Two Upcoming Investor Conferences 2Kastle Therapeutics Announces Key Additions to Commercial Leadership 2Kastle Therapeutics Announces Key Additions to Commercial Leadership 3
(Date:9/2/2015)... , ... September 02, 2015 , ... ... imaging, content, records and case management solutions and services to both government and ... Image Re-sizing and Image Clean-up utility for IBM’s Datacap document capture platform. ...
(Date:9/2/2015)... ... September 02, 2015 , ... “ G-Hold ” was ... and coolest technology products available to consumers. Amanda Forstrom, a technology expert and special ... designed for people to comfortably hold a tablet while reducing the likelihood of it ...
(Date:9/2/2015)... ... , ... Pentec Health, Inc., a national leader in outsourced pharmacy services, has ... year. Less than 5 % of this year’s 5000 honorees share the “six-time” recognition; ... 3-year revenue growth rate of 65% sustained its most recent achievement. As an Inc. ...
(Date:9/2/2015)... ... ... Mobile working is increasingly more important, as business professionals are looking to ... are being launched, and mobile device usage as a whole is something people around ... personal lives. What's more people are expecting mobile versions of their favorite software. , ...
(Date:9/1/2015)... ... September 01, 2015 , ... For many men, the first thing they notice when they ... forced to wear a looser fitting shirt with a collar that doesn’t close against the ... between their collar and skin all day because it’s uncomfortable. Now men in suits ...
Breaking Medicine News(10 mins):Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2
... of hope for visually- impaired patients.Retinal cell transplants can ... possibilities for them. Researchers at the University of Texas, ... a predisposition to blindness.// Experiments showed that the rats ... animals with normal vision. ,This is an ...
... Coffee is a very good stimulant in day to day ... memory performance that happens as the day progresses. During the ... adults compared to late afternoon.// For researchers at the University ... memory performance throughout the day. ,They had about ...
... that if women drink too much coffee during pregnancy can ... fits.//Studies have found that caffeine may be linked to the ... have been briefly starved of oxygen. ,A research team ... cells from the hippocampus, a part of the brain that ...
... Andhra Pradesh chief minister Chandrababu Naidu has set into ... in the port town of Vishakhapatnam. By providing world-class ... to attract global pharmaceutical companies to the city for ... 2005. The ‘Pharma City’ will be developed by private ...
... the disease gradually ended around the world. But stockpiles ... US, Russia and possibly other nations.// Recent fears of ... used to introduce the potentially deadly disease into the ... a potential outbreak. If introduced into America or Europe, ...
... a diet rich in butter and other fats, has led ... staple of the French diet. //Scientists say they have discovered ... known as polyphenols. ,Polyphenols inhibit the production ... Polyphenols in red wine decreases the amount of the peptide ...
Cached Medicine News:
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: